Clinical Trial Search

Primary: Proportions of Participants With Mean Urinary Free Cortisol (mUFC) Categorization Based on Upper Limit of Normal (ULN) — 0; 1; 50; 26 Participants

Primary: Number of Participants Who Complete Treatment With >90% Adherence — 223; 211 Participants — p=0.07

Primary: Number of Participants With Adverse Drug Reactions — 2 Participants

Primary: Score on Feasibility of Intervention Measure (FIM) Questionnaire — 5.0 score on a scale

Primary: Area Under Curve (AUC) of Disease Activity Score Based on a 28 Jointcount and C-reactive Protein (DAS28CRP) — 297.4; 300.7 units on a scale*week — p=<0.05

Primary: Objective Response Rate (ORR) — 0; 2; 2; 2 Participants

Primary: Overall Response Rate (ORR) — 53.45; 51.85; 57.14; 50.00 percentage of participants

Primary: Number of Alcoholic Drinks Consumed Per Week — 9.1; 16.5 Drinks per week

Primary: Percentage of Participants With a Toxicity — 6; 7; 24 Percentage of participants

Primary: Prolapse and Incontinence Knowledge Questionnaire (PIKQ) — 17; 17; 21; 21 score on a scale

Primary: Percentage Vital Bone Formation — 37.33; 40.76; 24.46; 23.85 percentage of vital bone formation

Primary: Study Phase Primary Endpoint: Percentage of Time in Range (TIR 70 to 180 mg/dL [3.9-10.0 mmol/L]) - Non-inferiority Test — 68.34; 58.34 percentage of time

Primary: Number of Participants Experiencing a Safety Event — 0; 1 Participants

Primary: Union Rates — 23 joints fused

Primary: Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated Relapses — 0.122; 0.130 relapses per participant year — p=0.6691